Therefore, in this real‐world study, data on treatment outcomes were analyzed to compare crizotinib with platinum‐based doublet chemotherapy as first‐line treatment in ROS1‐positive NSCLC patients. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.